Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry
Language English Country Greece Media print
Document type Journal Article
PubMed
26026110
PII: 35/6/3455
Knihovny.cz E-resources
- Keywords
- Bevacizumab, FOLFIRI, XELIRI, colorectal cancer,
- MeSH
- Bevacizumab MeSH
- Adult MeSH
- Fluorouracil administration & dosage MeSH
- Antibodies, Monoclonal, Humanized administration & dosage MeSH
- Camptothecin administration & dosage analogs & derivatives MeSH
- Colorectal Neoplasms drug therapy epidemiology pathology MeSH
- Leucovorin administration & dosage MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Metastasis MeSH
- Liver Neoplasms drug therapy epidemiology pathology secondary MeSH
- Disease-Free Survival MeSH
- Antineoplastic Combined Chemotherapy Protocols administration & dosage MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic MeSH
- Names of Substances
- Bevacizumab MeSH
- Fluorouracil MeSH
- Antibodies, Monoclonal, Humanized MeSH
- Camptothecin MeSH
- Leucovorin MeSH
AIM: To retrospectively compare the efficacy of two irinotecan-based chemotherapy regimens combined with bevacizumab in first-line therapy of metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: The data of 558 patients with mCRC treated with first-line bevacizumab plus irinotecan-containing regimen were obtained from the national CORECT registry that collects data of all patients with mCRC treated with targeted-agents. The treatment outcomes of patients treated with bevacizumab plus irinotecan, 5-fluorouracil and folinic acid (FOLFIRI) were compared to patients treated with bevacizumab plus irinotecan and capecitabine (XELIRI). RESULTS: Among 4,312 patients with CRC treated with bevacizumab, only 13% (558) received irinotecan-based chemotherapy. No significant differences were observed in terms of progression-free survival and overall survival between FOLFIRI and XELIRI groups. Moreover, the toxicity of both regimens was also comparable. CONCLUSION: This retrospective analysis confirms the comparable activity of FOLFIRI and XELIRI regimens when combined with bevacizumab.
